Published Health care and economic evaluation studies from India

#.Sinha A, Bahuguna P, Gupta SS, Kuruba YP, Poluru R, Mathur A, Raja D, Raut AV, Mahajan KS, Sudhakar R, Kulkarni B, Pandey RM, Arora NK, Prinja S. Study protocol for economic evaluation of probiotic intervention for prevention of neonatal sepsis in 0-2-month old low-birth weight infants in India: the ProSPoNS trial. BMJ Open. 2023 Mar 29;13(3):e068215. doi: 10.1136/bmjopen-2022-068215.

#.Prinja S, Sharma A, Nadipally S, Rana SK, Bahuguna P, Rao N, Chakraborty G, Shankar M, Rai V. Impact and cost-effectiveness evaluation of nutritional supplementation and complementary interventions for tuberculosis treatment outcomes under mukti pay-for-performance model in Madhya Pradesh, India: A study protocol. Int J Mycobacteriol. 2023 Jan-Mar;12(1):82-91. doi: 10.4103/2212-5531.307071.

#.Jyani G, Prinja S, Garg B, Kaur M, Grover S, Sharma A, Goyal A. Health-related quality of life among Indian population: The EQ-5D population norms for India. J Glob Health. 2023 Feb 17;13:04018.

#.Chugh Y, Jyani G, Trivedi M, Albert S, Kar SS, Patro B, Raman S, Rajsekar K, Baker RM, Donaldson C, Prinja S. Protocol for estimating the willingness-to-pay-based value for a quality-adjusted life year to aid health technology assessment in India: a cross-sectional study. BMJ Open. 2023 Feb 16;13(2):e065591.

#.Baranwal AK, Prinja S, Kaur N. Congenital Heart Disease: Would It Be the Key Driver of Infant Survival During Amrit Kaal (2022-2047)? Indian Pediatr. 2023 Feb 15;60(1):98-102.

#.Dixit J, Prinja S, Jyani G, Bahuguna P, Gupta A, Vijayvergiya R, Kumar R. Evaluating efficiency and equity of prevention and control strategies for rheumatic fever and rheumatic heart disease in India: an extended cost-effectiveness analysis. Lancet Glob Health. 2023, Feb 14; 11: e445-55.

#.Gupta D, Singh A, Gupta N, Mehra N, Bahuguna P, Aggarwal V, Krishnamurthy MN, Roy PS, Malhotra P, Gupta S, Kumar L, Kataki A, Prinja S. Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India. JCO Glob Oncol. 2023 Feb;9:e2200246.

#.Chauhan AS, Prinja S, Selvaraj S, Gupta A, Muraleedharan VR, Sundararaman T. Cost of delivering primary healthcare services through public sector in India. Indian J Med Res. 2023 Jan 2. [Epub ahead of print]

#.Singh MP, Popli R, Brar S, Rajsekar K, Sachin O, Naik J, Kumar S, Sinha S, Singh V, Patel P, Verma R, Hazra A, Misra R, Mehrotra D, Biswal SB, Panigrahy A, Gaur KL, Pankaj JP, Sharma DK, Madhavi K, Madhusudana P, Narayanasamy K, Chitra A, Velhal GD, Bhondve AS, Bahl R, Kaur S, Prinja S. CHSI costing study-Challenges and solutions for cost data collection in private hospitals in India. PLoS One. 2022 Dec 12;17(12):e0276399.

#.Prinja S, Singh MP, Aggarwal V, Rajsekar K, Gedam P, Goyal A, Bahuguna P. Impact of India's publicly financed health insurance scheme on public sector district hospitals: A health financing perspective. Lancet Regional Health-Southeast Asia. Dec 2022; 9:100123

#.Chauhan AS, Guinness L, Bahuguna P, Singh MP, Aggarwal V, Rajsekhar K, Tripathi S, Prinja S. Cost of hospital services in India: a multi-site study to inform provider payment rates and Health Technology Assessment. BMC Health Serv Res. 2022 Nov 14; 22(1):1343.

#.Chugh Y, Bahuguna P, Sohail A, Rajsekar K, Muraleedharan VR, Prinja S. Development of a Health Technology Assessment Quality Appraisal Checklist (HTA-QAC) for India. Appl Health Econ Health Policy. 2022 Oct 19:1-12. doi: 10.1007/s40258-022-00766-5.

#.Gupta N, Pandey AK, Dimri K, Jyani G, Goyal A, Prinja S. Health-related quality of life among breast cancer patients in India. Support Care Cancer. 2022 Oct 12. doi: 10.1007/s00520-022-07395-7

#.Kumar D, Prinja S. Costing of services under National Tuberculosis Elimination Program at public health facilities of northern India. Indian J Tuberc. 2022. Epub 2022 May 27. doi: 10.1016/j.ijtb.2022.05.009.

#.N Kaur, R Vijayvergiya, S Prinja, J Dixit, SK Sahoo, G Kasinadhuni. Economic Impact And SafetY of Same-Day Discharge Following Percutaneous Coronary Intervention: A Tertiary-Care Centre Experience From Northern India (EASY-SDD). Cardiovascular Revascularization Medicine. 2022; 40: 71-77.

#.Purohit N, Prinja S. The Dynamics of Health, Productivity, and Development: A Policy Prescription. Productivity. 2022; 62 (4).

#.Gupta N, Chugh Y, Chauhan AS, Pramesh CS, Prinja S. Cost-effectiveness of Post-Mastectomy Radiotherapy (PMRT) for breast cancer in India: An economic modelling study. The Lancet Regional Health-Southeast Asia. 2022 Aug 9:100043.

#.Bahuguna, P., Masaki, E., Jeet, G. et al. Financing Comprehensive Immunization Services in Lao PDR: A Fiscal Space Analysis From a Public Policy Perspective. Appl Health Econ Health Policy 21, 131–140 (2023).

#.Gupta N, Gupta D, Dixit J, Mehra N, Singh A, Krishnamurthy MN, Jyani G, Rajsekhar K, Kalaiyarasi JP, Roy PS, Malik PS. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor- Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women. Applied Health Economics and Health Policy. 2022 May 10:1-3.

#.Purohit N, Chugh Y, Bahuguna P, Prinja S. COVID-19 Management: The Vaccination Drive in India. Health policy and technology. 2022 May 5:100636.

#.Singh, L. M., Siddhanta, A., Singh, A. K., Prinja, S., Sharma, A., Sikka, H., & Goswami, L. (2022). Potential Impact of the Insurance on Catastrophic Health Expenditures Among the Urban Poor Population in India. Journal of Health Management.

#.Brar S, Purohit N, Singh G, Prinja S, Kaur M, Lakshmi PV. Health system readiness for roll out of the Ayushman Bharat Health and Wellnes Centres-Early experiences from Punjab State. Journal of Family Medicine and Primary Care. 2022 Mar 18;11(4):1354-60.

#.Gupta N, Nehra P, Chauhan AS, Mehra N, Singh A, Krishnamurthy MN, Rajsekhar K, Kalaiyarasi JP, Roy PS, Malik PS, Mathew A. Cost Effectiveness of Bevacizumab Plus Chemotherapy for the Treatment of Advanced and Metastatic Cervical Cancer in India—A Model-Based Economic Analysis. JCO Global Oncology. 2022 Mar;8:e2100355.

#.Raithatha, D., Sahu, J.K., Bhanudeep, S. et al. Financial Burden in Families of Children with West Syndrome. Indian J Pediatr 89, 118–124 (2022).

#.Makkar JK, Goyal A, Sharma R, Kumar V, Ghai B, Prinja S, Singh NP. Cross Cultural Adaptation and Validation of Hindi Version of WHOQOL-BREF in Patients With Chronic Low Back Pain.

#.Jyani G, Sharma A, Prinja S, Kar SS, Trivedi M, Patro BK, Goyal A, Purba FD, Finch AP, Rajsekar K, Raman S. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set. Value in Health.

#.Kaur A, Saini SK, Kaur G, Prinja S. Quality of life of diabetes patients in North India: A comparison of different methodologies. International Journal of Noncommunicable Diseases. 2022 Jan 1;7(1):22.

#.Chugh Y, Katoch S, Sharma D, Bahuguna P, Duseja A, Kaur M, Dhiman RK, Prinja S. Health-Related Quality of Life Among Liver Disorder Patients in Northern India. Indian J Community Med. 2022 Jan-Mar;47(1):76-81. doi: 10.4103/ijcm.ijcm_1033_21. Epub 2022 Mar 16. PMID: 35368487; PMCID: PMC8971888.

#.Kaur G, Chauhan AS, Prinja S, Teerawattananon Y, Muniyandi M, Rastogi A, Jyani G, Nagarajan K, Lakshmi PV, Gupta A, Selvam JM. Cost-effectiveness of population-based screening for diabetes and hypertension in India: an economic modelling study. The Lancet Public Health. 2022 Jan 1;7(1):e65-73.

#.Prinja S, Gupta N. Value-based pricing for cancer drugs in India. Cancer Research, Statistics, and Treatment. 2021 Jul 1;4(3):559.

#.Gupta A, Sharda S, Jyani G, Prinja S, Goyal A, Gauba K. Modelling the impact of increase in sugar price on dental caries in India. Community Dent Oral Epidemiol. 2021;00:1–7.

#.Gupta R, Singhal GL, Goyal A, Kaur G, Purohit N, Prinja S. Combatting the imbalance of sex ratio at birth: medium-term impact of India’s National Programme of Beti Bachao Beti Padhao in the Haryana State of India. Health Policy and Planning. 2021 Dec;36(10):1499-507.

#.Brar S, Purohit N, Prinja S, Singh G, Bahuguna P, Kaur M. What and how much do the community health officers and auxiliary nurse midwives do in health and wellness centres in a block in Punjab? A time-motion study. Indian J Public Health 2021;65:275-9

#.Gupta D, Jyani G, Ramachandran R, Bahuguna P, Ameel M, Dahiya BB, Kohli HS, Prinja S, Jha V. Peritoneal dialysis–first initiative in India: a cost-effectiveness analysis. Clinical Kidney Journal, 2021, 1–8. doi: 10.1093/ckj/sfab126

#.Gupta N, Jyani G, Rajsekar K, Gupta R, Nagar A, Gedam P, Prinja S. Application of Health Technology Assessment for Oncology Care in India: Implications for Ayushman Bharat Pradhan Mantri Jan Aarogya Yojana. Indian Journal of Medical and Pediatric Oncology. 2021.

#. Prinja S, Dixit J, Gupta N, Mehra N, Singh A, Krishnamurthy MN, Gupta D, Rajsekar K, Kalaiyarasi JP, Roy PS, Malik PS, Mathew A, Pandey A, Malhotra P, Gupta S, Kumar L, Kataki A, Singh G. Development of National Cancer Database for Cost and Quality of Life (CaDCQoL) in India: a protocol. BMJ Open. 2021 Jul 29;11(7):e048513. doi: 10.1136/bmjopen-2020-048513. PMID: 34326050; PMCID: PMC8323373.

1.Dixit J, Brar S, Prinja S. Burden of Group A Streptococcal Pharyngitis, Rheumatic Fever, and Rheumatic Heart Disease in India: A Systematic Review and Meta-Analysis. Indian J Pediatr. 2021 Aug 11. doi: 10.1007/s12098-021-03845-y. Online ahead of print.

2.Jyani G, Prinja S, Kar SS, et al Valuing health-related quality of life among the Indian population: a protocol for the Development of an EQ-5D Value set for India using an Extended design (DEVINE) Study BMJ Open 2020;10:e039517. doi: 10.1136/bmjopen-2020-039517.

3. Singh MP, Chauhan AS, Rai B, Ghoshal S, Prinja S. Cost of Treatment for Cervical Cancer in India. Asian Pac J Cancer Prev. 2020;21(9):2639-2646. Published 2020 Sep 1. doi:10.31557/APJCP.2020.21.9.2639.

4. Jyani G, Chauhan AS, Rai B, Ghoshal S, Srinivasan R, Prinja S. Health-related quality of life among cervical cancer patients in India. Int J Gynecol Cancer. 2020 Aug 11:ijgc-2020-001455. doi: 10.1136/ijgc-2020-001455. Epub ahead of print. PMID: 32788265.

5. Bahuguna P, Khaduja, Prinja S. Economic Analysis of Delivering Postpartum Intrauterine Contraceptive Device Services in India. Indian J Commun Med. 2019; 44 (2): 147-51

6. Chugh Y, Dhiman RK, Premkumar M, Prinja S, Grover GS, Bahuguna P. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India. PLoS One. 2019; 14(8): e0221769.

7. Sharma A, Prinja S, Sharma A, Gupta A, Arora S. Cost of Anti-Retroviral Treatment for HIV Patients in two treatment centres of North India. International Journal of STD & AIDS. 2019. 30(8):769-778.

8. Prinja S, Chauhan AS, Bahuguna P, Selvaraj S, Muraleedharan VR, Sundararaman T. Cost of Delivering Secondary Healthcare Through the Public Sector in India. Pharmacoecon Open. 2019 Aug 29. doi: 10.1007/s41669-019-00176-9.

9. Prinja S, Sharma YP, Dixit J, Thingnam SS, Kumar R. Cost of treatment of valvular heart disease at a tertiary hospital in North India: Policy Implications. Pharmacoeconomics Open. 2019.

10. Prinja S, Gupta A, Bahuguna P, Nimesh R. Cost analysis of implementing mHealth intervention for maternal, newborn & child health care through community health workers: assessment of ReMIND program in Uttar Pradesh, India. BMC Pregnancy Childbirth. 2018 Oct 3;18(1):390.

11. Kaur G, Prinja S, Malhotra P, Lad DP, Prakash G, Khadwal A, Ramachandran R, Varma S. Cost of Treatment of Multiple Myeloma in a Public Sector Tertiary Care Hospital of North India.Indian J Hematol Blood Transfus. 2018 Jan;34(1):25-31.

12. Chauhan AS, Prinja S, Ghoshal S, Verma R, Oinam AS. Cost of treatment for head and neck cancer in India. PLoS One. 2018;13(1):e0191132.

13. Kaur G, Prinja S, Ramachandran R, Malhotra P, Gupta KL, Jha V. Cost of hemodialysis in a public sector tertiary hospital of India. Clin Kidney J. 2018;11(5):726-733.

14. Prinja S, Bahuguna P, Duseja A, Kaur M, Chawla YK. Cost of Intensive Care Treatment for Liver Disorders at Tertiary Care Level in India. Pharmacoecon Open.2018;2(2):179-190.

15. Prinja S, Gupta A, Bahuguna P, Nimesh R. Cost analysis of implementing mHealth intervention for maternal, newborn & child health care through community health workers: assessment of ReMIND program in Uttar Pradesh, India.BMC Pregnancy Childbirth. 2018 Oct 3;18(1):390. doi: 10.1186/s12884-018-2019-3.

16. Kaur G, Prinja S, Ramachandran R, Malhotra M, Gupta KL, Jha V. Cost of hemodialysis in a public sector tertiary hospital of India. Clinical Kidney Journal. Clin Kidney J. 2018 Oct; 11(5): 726–733.doi: 10.1093/ckj/sfx152.

17. Jeet G, Prinja S, Aggarwal AK. Cost analysis of a simulation based training for Health workforce in India. Indian J Public Health. 2017. Apr-Jun;61(2):92-98. doi: 10.4103/ijph.IJPH_189_15.

18. Prinja S, Balasubramanian D, Jeet G, Verma R, Kumar D, Bahuguna P, et al. Cost of delivering secondary-level health care services through public sector district hospitals in India. Indian J Med Res. 2017 Sep;146(3):354-361.

19. Sangwan A, Prinja S, Aggarwal S, Jagnoor J, Bahuguna P, Ivers R. Cost of Trauma Care in Secondary- and Tertiary-Care Public Sector Hospitals in North India. Appl Health Econ Health Policy. 2017;15(5):681-692.

20. Prinja S, Gupta A, Verma R, Bahuguna P, Kumar D, Kaur M, Kumar R. Cost of Delivering Health Care Services in Public Sector Primary and Community Health Centres in North India. PLoS One. 2016;11(8):e0160986.

21. Thakur J, Prinja S, Jeet G, Bhatnagar N. Costing of a State-Wide Population Based Cancer Awareness and Early Detection Campaign in a 2.67 Million Population of Punjab State in Northern India. Asian Pac J Cancer Prev. 2016;17(2):791-7.

22. Prinja S, Jeet G, Verma R, Kumar D, Bahuguna P, Kaur M, et al. Economic analysis of delivering primary health care services through community health workers in 3 North Indian states. PLoS One 2014; 9 : e91781.

23. Prinja S, Mazumder S, Taneja S, Bahuguna P, Bhandari N, Mohan P, et al. Cost of delivering child health care through community level health workers: How much extra does IMNCI program cost? J Trop Pediatr 2013; 59 : 489-9.

24. Chatterjee S, Laxminarayan R. Costs of surgical procedures in Indian hospitals. BMJ Open. 2013;3(6). pii: e002844.

26. Prinja S, Manchanda N, Mohan P, Gupta G, Sethy G, Sen A, van den Hombergh H, Kumar R. Cost of neonatal intensive care delivered through district level public hospitals in India. Indian Pediatr. 2013;50(9):839-46.

27. Chatterjee S, Levin C, Laxminarayan R. Unit cost of medical services at different hospitals in India. PLoS One. 2013;8(7):e69728.

28. Prinja S, Manchanda N, Aggarwal AK, Kaur M, Jeet G, Kumar R. Cost & efficiency evaluation of a publicly financed & publicly delivered referral transport service model in three districts of Haryana State, India. Indian J Med Res. 2013;138(6):1003-11.

29. Chauhan AS, Prinja S, Ghoshal S, Verma R. Cost-effectiveness of treating head and neck cancer using intensity-modulated radiation therapy: implications for cancer control program in India. Int J Technol Assess Health Care. 2020 Sep 23:1-8. doi: 10.1017/S0266462320000677

30. Chauhan AS, Prinja S, Srinivasan R, Rai B, Malliga JS, Jyani G, Gupta N, Ghoshal S. Cost effectiveness of strategies for cervical cancer prevention in India. PLoS One. 2020 Sep 1;15(9):e0238291. doi: 10.1371/journal.pone.0238291. PMID: 32870941; PMCID: PMC7462298.

31. Jyani G, Prinja S, Ambekar A, Bahuguna P, Kumar R. Health impact and economic burden of alcohol consumption in India. International Journal of Drug Policy. 2019 Jul 1;69:34-42.

32. Chugh Y, Dhiman RK, Premkumar M, Prinja S, Singh Grover G, Bahuguna P. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India. PLoS One. 2019 Aug 29;14(8):e0221769. doi: 10.1371/journal.pone.0221769. PMID: 31465503; PMCID: PMC6715223.

33. Prinja S, Chauhan AS, Bahuguna P, Selvaraj S, Muraleedharan VR, Sundararaman T. Cost of Delivering Secondary Healthcare Through the Public Sector in India. Pharmacoecon Open. 2019 Aug 29. doi: 10.1007/s41669-019-00176-9. [Epub ahead of print]

34. Prinja S, Bahuguna P, Gupta A, Nimesh R, Gupta M, Thakur JS. Cost effectiveness of mHealth intervention by community health workers for reducingmaternal and newborn mortality in rural Uttar Pradesh, India. Cost Eff ResourAlloc. 2018 Jun 25;16:25. doi: 10.1186/s12962-018-0110-2.

35. Gupta N, Verma RK, Prinja S, Dhiman RK. Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India. Journal of Clinical and Experimental Hepatology. 2018 Oct 31.

36. John M J, Jyani G, Jindal A, Mashon RS, Mathew A, Kakkar S, Bahuguna P, Prinja S. Cost Effectiveness of Hematopoietic Stem Cell Transplantation Compared with Transfusion Chelation for Treatment of Thalassemia Major. Biol Blood Marrow Transplant. 2018 Oct;24(10):2119-2126. doi: 10.1016/j.bbmt.2018.04.005.

37. Prinja S, Bahuguna P, Faujdar DS, Jyani G, Srinivasan R, Ghoshal S, Suri V,Singh MP, Kumar R. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program. Cancer. 2017 Sep 1;123(17):3253-3260. doi: 10.1002/cncr.30734.

38. Prinja S, Kaur G, Malhotra P, Jyani G, Ramachandran R, Bahuguna P, Varma S.Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional Chemotherapy for Treatment of Multiple Myeloma in India. Indian J Hematol Blood Transfus. 2017 Mar;33(1):31-40. doi: 10.1007/s12288-017-0776-1.

39. Prinja S, Bahuguna P, Mohan P, Mazumder S, Taneja S, Bhandari N, van denHombergh H, Kumar R. Cost Effectiveness of Implementing Integrated Management of Neonatal and Childhood Illnesses Program in District Faridabad, India. PLoS One. 2016 Jan 4;11(1):e0145043. doi: 10.1371/journal.pone.0145043.

40. Dhivya PS, Swathy G, Pal S. Pharmacoeconomics of antihypertensive drugs prescribed in a multispecialty hospital in South India. Asian J Pharm. 2014;8(3):178–82.

41. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: A combined analysis of 12 mathematical models. Lancet Glob Heal. 2014;2(1):e23–34.

42. Rheingans R, Anderson JD, Anderson B, Chakraborty P, Atherly D, Pindolia D. Estimated impact and cost-effectiveness of rotavirus vaccination in India: effects of geographic and economic disparities. Vaccine [Internet]. 2014;32Suppl 1:A140–50.

43. Singh K. Economic evaluation of Japanese encephalitis vaccination programme in Uttar Pradesh, India : a cost-benefit study. J Vector Borne Dis. 2014;51(1):47–52.

44. Vassall A, Pickles M, Chandrashekar S, Boily M-C, Shetty G, Guinness L, et al. Cost-effectiveness of HIV prevention for high-risk groups at scale: an economic evaluation of the Avahan programme in south India. Lancet Glob Heal [Internet]. 2014;2(9):e531–40.

45. Vijendra R, Kumar A, Girish K, Harsha R, Reddy V, Lakshmi P. Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome. Indian J Pharmacol.2014;46(4):372.

46. Bindoria SV, Devkar R, Gupta I, Ranebennur V, Saggurti N, Ramesh S, et al. Development and pilot testing of HIV screening program integration within public/primary health centers providing antenatal care services in Maharashtra, India. BMC Res Notes. 2014;7(1):177.

47. Vassall A, Chandrashekar S, Pickles M, Beattie T, Shetty G, Bhattacharjee P, et al. Community mobilisation and empowerment interventions as part of HIV prevention for female sex workers in Southern India: A cost-effectiveness analysis. 2014;9(10):e110562.

48. Aggarwal K, Khandpur S, Khanna N, Sharma VK, Pandav CS. Comparison of clinical and cost-effectiveness of psoralen? ultraviolet A versus psoralen? sunlight in the treatment of chronic plaque psoriasis in a developing economy. Int J Dermatol. 2013;52(4):478–85.

49. Brown HS, Stigler M, Perry C, Dhavan P, Arora M, Reddy KS. The cost-effectiveness of a school-based smoking prevention program in India. Health Promot Int. 2013;28(2):178–86.

50. Clark AD, Griffiths UK, Abbas SS, Rao KD, Privor-Dumm L, Hajjeh R, et al. Impact and cost-effectiveness of haemophilusinfluenzae type b conjugate vaccination in india. J Pediatr [Internet]. 2013;163(1):S60–72.

51. Gupta M, Prinja S, Kumar R, Kaur M. Cost-effectiveness of Haemophilusinfluenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India. Health Policy Plan. 2013;28(1):51–61.

52. Marseille E, Lohse N, Jiwani A, Hod M, Seshiah V, Yajnik CS, et al. The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel. J Matern Fetal Neonatal Med. 2013;26(8):802–10.

53. Rachapelle S, Legood R, Alavi Y, Lindfield R, Sharma T, Kuper H, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in india. Ophthalmology [Internet]. 2013;120(3):566–73.

54. Sriram S, Aiswaria V, Cijo A, Mohankumar T. Antibiotic sensitivity pattern and cost-effectiveness analysis of antibiotic therapy in an Indian tertiary care teaching hospital. J Res Pharm Pract. 2013;2(2):70.

55. Thaker S, Mehta D, Shah H, Dave J, Kikani K. A comparative study to evaluate efficacy, safety and cost-effectiveness between Whitfield′s ointment + oral fluconazole versus topical 1 % butenafine in tinea infections of skin. Indian J Pharmacol. 2013;45(6):622.

56. Thaker S, Mehta D, Shah H, Dave J, Mundhava S. A comparative randomized open label study to evaluate efficacy, safety and cost effectiveness between topical 2 % sertaconazole and topical 1 % butenafine in tinea infections of skin.Indian J Dermatol. 2013;58(6):451.

57. Van’tHoog AH, Cobelens F, Vassall A, Van Kampen S, Dorman SE, Alland D, et al. Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: A decision analysis. PLoS One. 2013;8(12):e82786.

58. Venkatesh KK, Becker JE, Kumarasamy N, Nakamura YM, Mayer KH, Losina E, et al. Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India. PLoS One. 2013;8(5):e64604.

59. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013;369:1715–25.

60. Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis. Vaccine [Internet]. 2013;31(42):4902–10.

61. Buttorff C, Hock RS, Weiss HA, Naik S, Araya R, Kirkwood BR, et al. Economic evaluation of a task-shifting intervention for common mental disorders in India. Bull World Health Organ. 2012;90(11):813–21.

62. Pandav C. Economic evaluation of iodine deficiency disorder control program in Sikkim: a cost effectiveness study. Indian J Public Health. 2012;56(1):37.76.

63. Lee BY, Bacon KM, Shah M, Kitchen SB, Connor DL, Slayton RB.The economic value of a visceral leishmaniasis vaccine in Bihar State, India. Am J Trop Med Hyg. 2012;86(3):417–25.

64. Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, et al. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012;7(4):e36001.

65. Reid S. Estimating the burden of disease from unsafe injections in India: a cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence. Indian J Community Med. 2012;37(2):89–94.

66. Burke MJ, Shenton RC, Taylor MJ. The economics of screening infants at risk of hearing impairment: an international analysis. Int J Pediatr Otorhinolaryngol. 2012;76(2):212–8.

67. Pandav CS. Economic evaluation of iodine deficiency disorder control program in Sikkim: a cost effectiveness study. Indian J Public Heal. 2012;56(1):37–43.

68. Alexander A, John KR, Jayaraman T, Oommen A, VenkataRaghava M, Dorny P, et al. Economic implications of three strategies for the control of taeniasis. Trop Med Int Health. 2011;16(11):1410–6.

69. Donaldson EA, Waters HR, Arora M, Varghese B, Dave P, Modi B. A cost-effectiveness analysis of India’s 2008 prohibition of smoking in public places in Gujarat.Int J Environ Res Public Health. 2011;8(5):1271–86.

70. Dowdy DW, Steingart KR, Pai M. Serological testing versus other strategies for diagnosis of active tuberculosis in india: a cost-effectiveness analysis. PLoS Med. 2011;8(8):e1001074.

71. Dranitsaris G, Truter I, Lubbe MS, Sriramanakoppa NN, Mendonca VM, Mahagaonkar SB. Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value. Int J Technol Assess Health Care. 2011;27(1):23–30.

72. Esposito DH, Tate JE, Kang G, Parashar UD. Projected impact and cost-effectiveness of a rotavirus vaccination program in India, 2008.Clin Infect Dis. 2011;52(2):171–7.

73. Goodchild M, Sahu S, Wares F, Dewan P, Shukla RS, Chauhan LS, et al.A cost-benefit analysis of scaling up tuberculosis control in India.Int J Tuberc Lung Dis. 2011;15(3):358–62.

74. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the crash-2 trial. PLoS One. 2011;6(5):e18987.

75. Lohse N, Marseille E, Kahn JG. Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus. Int J GynecolObstet [Internet]. 2011;115 Suppl:S20–5.

76. Massad E, Behrens BC, Coutinho F a B, Behrens RH. Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries. Malar J [Internet]. 2011;10(1):130.

77. Prinja S, Bahuguna P, Rudra S, Gupta I, Kaur M, Mehendale SM, et al. Cost effectiveness of targeted HIV prevention interventions for female sex workers in India. Sex Transm Infect. 2011;87(4):354–61.

78. Singh SP, Hirve S, Huda MM, Banjara MR, Kumar N, Mondal D. Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoSNegl Trop Dis. 2011;5(2):e960.

79. Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, et al. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 2010;50(3):416–25.

80. Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet. 2010;376(9754):1775–84

81. Chow J, Klein EY, Laxminarayan R. Cost-effectiveness of “golden mustard” for treating vitamin a deficiency in India.PLoS One. 2010;5(8):e12046.

81. Dandona L, Kumar SGP, Kumar GA, Dandona R. Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India. BMC Health Serv Res. 2010;10:117.

82. Goldie SJ, Sweet S, Carvalho N, Natchu UCM, Hu D. Alternative strategies to reduce maternal mortality in India: a cost-effectiveness analysis. PLoS Med. 2010;7(4):e1000264.

83. Jothi R, Ismail AM, Senthamarai R, Pal S. A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients.Indian J Pharmacol. 2010;42(6):362–5.

84. Mahajan R, Gupta A, Gupta RS, Gupta K. Efficacy, safety and cost-effectiveness of insulin sensitizers as add-on therapy in metabolic syndrome in patients with secondary sulfonylurea failure: a comparative study. J PharmacolPharmacother. 2010;1(2):82–6.

85. Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, et al. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoSNegl Trop Dis. 2010;4(9).

86. Mukherjee K. Cost-effectiveness of childbirth strategies for prevention of mother-to-child transmission of HIV among mothers receiving nevirapine in India. Indian J Community Med. 2010;35(1):29–33.

87. Schulman-Marcus J, Prabhakaran D, Gaziano TA. Pre-hospital ECG for acute coronary syndrome in urban India: a cost-effectiveness analysis. BMC CardiovascDisord. 2010;10:13.

88. Sutherland T, Meyer C, Bishai DM, Geller S, Miller S. Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: Cost-effectiveness, mortality, and morbidity reduction analysis. Int J GynecolObstet [Internet]. 2010;108(3):289–94.

89. Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, et al. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS One. 2010;5(9):1–9.

90. Bachewar NP, Thawani VR, Mali SN, Gharpure KJ, Shingade VP, Dakhale GN.Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies.Indian J Pharmacol. 2009;41(1):9–14.

91. Dabral M. Cost-effectiveness of supplementary immunization for measles in India.Indian Pediatr. 2009;46(3):957–62.

92. Frick KD, Riva-Clement L, Shankar MB. Screening for refractive error and fitting with spectacles in rural and urban India: cost-effectiveness. Ophthalmic Epidemiol. 2009;16(6):378–87.

93. Jeuland M, Cook J, Poulos C, Clemens J, Whittington D. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health. 2009;12(6):899–908.

94. Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, et al. Cost-effectiveness of artesunate for the treatment of severe malaria. Trop Med Int Heal. 2009;14(3):332–7.

95. Rob B, Vinod JA, Monica P, Balraj A, Job A, Norman G, et al. Costs and health effects of screening and delivery of hearing aids in Tamil Nadu, India: an observational study. BMC Public Health. 2009;9:135.

96. Rose J, Hawthorn RL, Watts B, Singer ME. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ. 2009;339:b3653.

97. Subramanian S, Sankaranarayanan R, Bapat B, Somanathan T, Thomas G, Mathew B, et al. Cost-effectiveness of oral cancer screening: Results from a cluster randomized controlled trial in India. Bull World Health Organ. 2009;87(3):200–6.

98. Sutherland T, Bishai DM. Cost-effectiveness of misoprostol and prenatal iron supplementation as maternal mortality interventions in home births in rural India.Int J GynecolObstet [Internet]. 2009;104(3):189–93.

99. Pantoja A, Lönnroth K, Lal SS, Chauhan LS.Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness.Int J Tuberc Lung Dis. 2009;13(6):705–12.

100. Olliaro P, Darley S, Laxminarayan R, Sundar S. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar. India. Trop Med Int Heal. 2009;14(8):918–25.

101. Bhagia L J, Sadhu HG. Cost-benefit analysis of installing dust control devices in the agate industry, Khambhat (Gujarat). Indian J Occup Environ Med. 2008;12(3):128–31.

102. Goldie SJ, O’Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008;26(32):4080–93.

103. Cook J, Jeuland M, Whittington D, Poulos C, Clemens J, Sur D, et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine. 2008;26(50):6305–16.

104. Kochhar P, Suvarna V, Duttagupta S, Sarkar S. Cost-effectiveness study comparing cefoperazone-sulbactam to a three-drug combination for treating intraabdominal infections in an Indian health-care setting. Value Health. 2008;11(Suppl 1):S33–8.

105. Okonkwo QL, Draisma G, Der Kinderen A, Brown ML, De Koning HJ. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst. 2008;100(18):1290–300.74.

106. Paul SB, Sreenivas V, Gulati MS, Madan K, Gupta AK, Mukhopadhyay S, et al. Economic evaluation of a surveillance program of hepatocellular carcinoma (HCC) in India.Hepatol Int. 2008;2(2):231–6.

107. Suraratdecha C, Ramana CV, Kaipilyawar S, Krishnamurthy J, Sivalenka S, Ambatipudi N, et al. Cost and effectiveness analysis of immunization service delivery support in Andhra Pradesh, India. Bull World Health Organ. 2008;86(3):221–8.

108. Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer. 2008;99(2):230–8.

109. Ferroussier O, Kumar MKA, Dewan PK, Nair PKJ, Sahu S, Wares DF, et al. Cost and cost-effectiveness of a public-private mix project in Kannur District Kerala, India, 2001–2002. Int J Tuberc Lung Dis. 2007;11(7):755–61. 45.

110. Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, et al. Clinical impact and cost effectivceness of antiretroviral therapy in India: starting criteria and second line therapy. AIDS. 2007;21(Suppl 4):S117–28.

111. Fung IC-H, Guinness L, Vickerman P, Watts C, Vannela G, Vadhvana J, et al. Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. BMC Public Health. 2007;7:195.

112. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions. Diabetes Care. 2007;30(10):2548–52.

113. Floyd K, Arora VK, Murthy KJR, Lonnroth K, Singla N, Akbar Y, et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ. 2006;84(05):437–45.

114. Kumar M, Birch S, Maturana A, Gafni A. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India. Health Policy (N Y). 2006;77(2):233–43.

115. Over M, Marseille E, Sudhakar K, Gold J, Gupta I, Indrayan A, et al. Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options. Sex Transm Dis. 2006;33(10):S145–52.

116. Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A. A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins - Enoxaparin, nadroparin and dalteparin: the ESCAPe-END study. Pharmacology. 2006;78(3):136–43.

117. Sood S, Nambiar D. Comparative cost-effectiveness of the components of a behavior change communication campaign on HIV/AIDS in North India. J Health Commun. 2006;11(Suppl 2):143–62.

118. Suraratdecha C, Jacobson J, Sivalenka S, Narahari D.A cost-effectiveness analysis of strategies for controlling Japanese encephalitis in Andhra Pradesh, India.J Pharm Financ Econ Policy. 2006;15(1):21–40.

119. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353(20):2158–68.

120. Legood R, Gray AM, Mahé C, Wolstenholme J, Jayant K, Nene BM, et al. Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected. Int J Cancer. 2005;117(6):981–7.

121. Bhatia MR, Fox-Rushby J, Mills A. Cost-effectiveness of malaria control interventions when malaria mortality is low: Insecticide-treated nets versus in-house residual spraying in India. SocSci Med. 2004;59(3):525–39.

122. Poulos C, Bahl R, Whittington D, Bhan MK, Clemens JD, Acosta CJ. A cost-benefit analysis of typhoid fever immunization programs in an Indian urban slum community. J Health PopulNutr. 2004;22(3):311–21.

123. Sahni M, Jindal K, Abraham M, Aruldas K, Puliyel JM. Hepatitis B Immunization: cost calculation in a community based study in India. Indian J Gastroenterol. 2004;23(1):16–8.

124. Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost effectiveness of universal hepatitis B immunization in a low income country with intermediate endimicity using a Markov model. J Hepatol. 2003;38(2):215–22.

125. Ghoshal UC, Aggarwal R, Baba CS. Recurrent duodenal ulcer haemorrhage: a pharmacoeconomic comparison of various management strategies. Expert OpinPharmacother. 2003;4:1593–603.

126. Gogtay NJ, Kadam VS, Desai S, Kamtekar KD, Dalvi SS, Kshirsagar NA.A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mumbai. India. J Assoc Physicians India. 2003;51:877–9.

127. Patel AB, Dhande LA, Rawat MS. Economic evaluation of zinc and copper use in treating acute diarrhea in children: a randomized controlled trial. Cost EffResourAlloc. 2003;1(1):7.

128. Patel V, Chisholm D, Rabe-Hesketh S, Dias-Saxena F, Andrew G, Mann A. Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: A randomised, controlled trial. Lancet. 2003;361(9351):33–9.

129. Prakash C. Crucial factors that influence cost effectiveness of Universal Hepatitis B immunization in India. Int J Technol Assess Health Care. 2003;19(1):28–40.

130. Krishnamoorthy K, Rajendran R, Sunish IP, Reuben R. Cost effectiveness of the use of vectrol control and mass drug administration, seperately or in combination, against lymphatic filariasis. Ann Trop Med Parasitol. 2002;96:S77–90.

131. Aggarwal R, Ghoshal UC, Naik SR. Treatment of Chronic hepatitis B with interferon-alpha: Cost-effectiveness in developing countries. Natl Med J India. 2002;15(6):320–7.

132. Ghoshal UC, Aggarwal R, Kumar S, Naik SR. Pneumatic dilation versus intrasphinctericbotulinum toxin injection in the treatment of achalasia cardia in India: an economic analysis. Indian J Gastroenterol. 2002;21(5):193–6.

133. Srivastava A, Srinivas G, Misra MC, Pandav CS, Seenu V, Goyal A. Cost-effectiveness analysis of laparoscopic versus minilaparotomy cholecystectomy for gallstone disease. A randomized trial.Int J Technol Assess Health Care. 2001;17(4):497–502.

134. Subramaniam B, Madan R, Sadhasivam S, Sennaraj B, Tamilselvan P, Rajeshwari S, et al. Dexamethasone is a cost-effective alternative to ondansertron in preventing PONV after paediatric strabismur repair. Br J Anaesth. 2001;86(1):84–9.

135. Singh A J, Garner P, Floyd K. Cost-effectiveness of public-funded options for cataract surgery in Mysore, India.Lancet. 2000;355(9199):180–4.

136. Awasthi S, Pande VK, Fletcher RH. Effectiveness and cost-effectiveness of albendazole in improving nutritional status of pre-school children in urban slums.Indian Pediatr. 2000;37(1):19–29.

137. Miller MA, Kane M. Routine hepatitis B immunisation in India: cost-effectiveness assessment. Indian J Pediatr. 2000;67(4):299–300.

138. Bhatia SJ, Kulkarni SG. Cost-effectiveness of Helicobacter pylori eradication in India: to live and let live … expensively? Indian J Gastroenterol. 1997;16(Suppl 1):S25–8.

139. Thomas K, Peter JV, Cherian AM, Guyatt G. Cost-effectiveness of inhaled β-agonists v. oral salbutamol in asthma: A randomized double-blind cross-over study. Natl Med J India. 1996;9(4):159–62.

140. McNeil BJ, Dudley RA, Hoop B, Metz C, Thompson M, Adelstein SJ.A cost-effectiveness analysis of screening for hepatitis B surface antigen in India.Med Decis Making. 1981;1(4):345–59.

141. McNeil BJ, Thompson M, Adelstein SJ. Cost effectiveness calculations for the diagnosis and treatment of tuberculous meningitis. Eur J Nucl Med. 1980;5(3):271–6.

142. Isaac MK, Kapur R. A cost-effectiveness analysis of three different methods of psychiatric case finding in the general population. Br J Psychiatry. 1980;137(6):540–6.

  • Content managed by:
  • Dept. of Community Medicine & School of Public Health PGIMER Chandigarh
  • Website hosted by :
  • Dept. of Community Medicine & School of Public Health PGIMER Chandigarh
    Last modified :
    March 16 2023 04:14:33.
  • Total visitor

  • © Copyright 2018

Please Submit Feedback